IP
CBIO

Intellectus Partners’s Crescent Biopharma CBIO Stock Holding History

Intellectus Partners’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-460
Closed -$9.65K – 286
2025
Q1 		$9.65K Hold
460
– – ﹤0.01% 267
2024
Q4 		$11.4K Hold
460
– – ﹤0.01% 272
2024
Q3 		$7.77K Hold
460
– – ﹤0.01% 264
2024
Q2 		$12.9K Sell
460
-47
-9% -$4.89K ﹤0.01% 258
2024
Q1 		$152K Hold
507
– – 0.04% 249
2023
Q4 		$120K Sell
507
-113
-18% -$17.6K 0.03% 239
2023
Q3 		$93K Sell
620
-115
-16% -$18.1K 0.03% 250
2023
Q2 		$128K Sell
735
-82
-10% -$13.7K 0.04% 253
2023
Q1 		$103K Hold
817
– – 0.03% 243
2022
Q4 		$248K Sell
817
-388
-32% -$57.2K 0.09% 218
2022
Q3 		$66K Buy
1,205
+325
+37% +$23.4K 0.02% 249
2022
Q2 		$53K Sell
880
-25
-3% -$1.85K 0.02% 239
2022
Q1 		$103K Buy
905
+100
+12% +$11.7K 0.03% 228
2021
Q4 		$116K Sell
805
-425
-35% -$77.1K 0.03% 260
2021
Q3 		$269K Hold
1,230
– – 0.07% 232
2021
Q2 		$285K Buy
1,230
+420
+52% +$107K 0.06% 238
2021
Q1 		$244K Buy
810
+710
+710% +$254K 0.07% 228
2020
Q4 		$38K Buy
+100
New +$35K 0.01% 232

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Intellectus Partners's CBIO Position: Q2 2025 in Review

Intellectus Partners sold out of Crescent Biopharma (CBIO) in Q2 2025, closing a stake of 460 shares — an estimated $9.65K sold.

Intellectus Partners first reported a position in CBIO in Q4 2020 and held it in 18 quarters. The position peaked at $285K in Q2 2021. 30 funds tracked by Wall St. Rank hold CBIO as of Q2 2025.

  • Intellectus Partners reported no remaining Crescent Biopharma position as of Q2 2025 after selling out during the quarter.
  • Intellectus Partners sold 460 Crescent Biopharma shares in Q2 2025, an estimated $9.65K.
  • Intellectus Partners first reported a position in Crescent Biopharma in Q4 2020 and held it in 18 quarters.
  • Intellectus Partners's Crescent Biopharma position peaked at $285K in Q2 2021.
  • 30 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2025.

Based on Intellectus Partners's 13F filing for Q2 2025, filed 5 Aug 2025.